Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Sanofi Consumer Healthcare India Ltd

| Unaudited Financial Results for the Quarter Ended March 31, 2026

Report Source

⬤28th Apr 26

Summary : Sanofi Consumer Healthcare India reports strong Q1 2026 results driven by product relaunches and robust sales growth, with an unmodified limited review.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of Materials Consumed (Q1 2026): 402 Million
  2. Purchases of stock in trade (Q1 2026): 181 Million
  3. Employee benefits expense (Q1 2026): 331 Million
  4. Total Expenses (Q1 2026): 1,441 Million
  5. Revenue from Operations (Q1 2026): 2,292 Million
  6. Other Income (Q1 2026): 56 Million
  7. Total Income (Q1 2026): 2,348 Million
  8. Sales of Product (Q1 2026): 2,063 Million
  9. Standalone, as no subsidiaries, associates, or joint ventures

Corporate Overview

  1. Domestic (India)
  2. Export
  3. Past product recalls (Depura Kids, Allegra Suspension, Combiflam Suspension) impacted sales comparability
  4. Single business segment: Pharmaceutical Business
  5. Formal and informative, reporting financial results
  6. Sales of products
  7. Service income
  8. Domestic sales
  9. Export sales

Risk Factors

  1. Potential impact of new labor codes.
  2. Past product recalls affected comparability.
  3. Single pharmaceutical business segment.
  4. Future regulatory changes.

Key Drivers

  1. Successful relaunch of key products.
  2. Strong domestic sales growth (15.5%).
  3. Exceptional export sales growth (144.4%).
  4. Increased profit for the period.

Auditor’s Report

  1. Unmodified conclusion on unaudited financial results (Limited Review)
  2. No material misstatement found during limited review
  3. Balancing figures for Q4 2025 were subject to limited review, not audit

Board Commentary

  1. Financial impact from New Labour Codes on employee benefits
  2. Comparability issues due to past product recalls
  3. Impact of new Labour Codes notified by Government of India
  4. Past product recalls (Depura Kids, Allegra Suspension, Combiflam Suspension)

Corporate Governance

  1. Audit Committee reviewed and approved financial results

Management Discussion & Analysis

Future Strategy

  1. Monitoring finalization of New Labour Codes and evaluating impact

Operational Focus Areas

  1. Assessing financial impact of New Labour Codes
  2. Monitoring and evaluating impact on employee benefits

Performance Drivers

  1. Successful relaunch of Combiflam Suspension, Allegra Suspension, Depura Kids
  2. 15.5% growth in domestic sales
  3. 144.4% growth in export sales on lower base

Risk Control Measures

  1. Monitoring and evaluating New Labour Codes impact
  2. Successful relaunch of previously recalled products

Critical Risks

  1. Uncertainty regarding financial impact of New Labour Codes
  2. Past product recalls affecting sales comparability
Dhanarthi

Built With ❤For Indian Investors & Researchers.

With Dhanarthi, stay a step ahead in the market using AI to identify strong stocks and support better financial decisions.

Download AppDhanarthi - AI Driven Stock Insights | Product Hunt

Request an AI Summary of dhanarthi.com

GoogleChatGPTClaudePerplexityGrok

Quick Links

  1. Calculators
  2. Screener
  3. Sectors
  4. Analysis
  5. Blogs
  6. News
  7. Glossary
  8. Pricing
  9. Contact Us

Stay Ahead with the Financial News & Insights

© 2026 Dhanarthi Research House. All Rights Reserved.

Privacy PolicyTerms & ConditionsDisclaimerCookie Policy

Dhanarthi is an AI-powered stock screening, data analytics, and educational research platform. We are NOT a SEBI-registered investment advisor, research analyst, broker, portfolio manager, or financial institution. All data, screening tools, and financial insights are provided strictly for educational and informational purposes to assist in independent research, and should not be construed as personalized investment advice. We do not offer portfolio management, execution of trades, lending services, or guaranteed returns. Investments in the stock market are subject to market risks. Please consult a qualified financial advisor before making any investment decisions.